Perrigo to Present at the UBS Global Consumer and Retail Conference
Rhea-AI Summary
Perrigo (NYSE: PRGO) announced that President and CEO Patrick Lockwood-Taylor will present at the UBS Global Consumer and Retail Conference on Wednesday, March 11, 2026 at 11:00 AM EDT. A live webcast will be available on Perrigo's investor website.
The presentation will cover the company’s consumer health strategy and recent developments; investors can access slides and a replay via the Perrigo investor page.
Positive
- None.
Negative
- None.
News Market Reaction – PRGO
On the day this news was published, PRGO gained 2.63%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $40M to the company's valuation, bringing the market cap to $1.56B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRGO fell 6.66% while key peers were mixed: PBH up 2.06%, AMRX down 0.82%, INDV down 2.5%, BHC down 1.13%, HCM down 1.57%. The magnitude of PRGO’s move diverges from peers, pointing to company-specific pressure rather than a sector-wide swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings results | Neutral | -1.5% | Q4 and FY2025 results with sales decline and large goodwill impairment. |
| Feb 19 | Dividend declaration | Positive | +2.1% | Announced quarterly cash dividend of $0.29 per share. |
| Feb 13 | Earnings date set | Neutral | +1.1% | Scheduled release and call for Q4 and FY2025 financial results. |
| Nov 05 | Earnings results | Negative | -25.2% | Q3 2025 sales decline and tempered outlook amid softer OTC demand. |
| Nov 05 | Strategic review | Neutral | -25.2% | Initiated strategic review of infant formula business and prior investment. |
Across recent events, PRGO’s price has typically moved in the same direction as the perceived tone of news, with notably sharp selloffs around earnings and strategic updates.
Over the last six months, Perrigo has focused on earnings performance, portfolio optimization, and capital returns. Earnings on Nov 5, 2025 and Feb 26, 2026 highlighted sales declines and a large $1.3B goodwill impairment alongside cost savings, prompting negative price reactions. A strategic review of the infant formula business on Nov 5, 2025 coincided with a steep drop. By contrast, the $0.29 quarterly dividend announced on Feb 19, 2026 saw a positive move. Today’s conference appearance fits into ongoing investor communication rather than a new financial inflection point.
Market Pulse Summary
This announcement highlights Perrigo’s participation in a major consumer and retail conference on March 11, 2026, offering management another platform to discuss strategy and recent results. In the months leading up to this event, the company reported a large $1.3B goodwill impairment, updated guidance, and continued portfolio review, alongside maintaining a $0.29 quarterly dividend. Investors may watch for any added color on cost-savings programs, category performance, and strategic reviews during the presentation.
Key Terms
over-the-counter (otc) medical
forward-looking statements regulatory
form 10-k regulatory
securities and exchange commission regulatory
AI-generated analysis. Not financial advice.
Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.
About Perrigo
Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in
Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
For more information, visit www.perrigo.com.
Forward-Looking Statements
This press release includes, and the matters discussed in Perrigo's presentation at the UBS Global Consumer and Retail Conference will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025.
Perrigo Contact
Bradley Joseph, Vice President, Global Investor Relations, (269) 686-3373, E-mail: bradley.joseph@perrigo.com
Nicholas Gallagher, Associate Director, Global Investor Relations, (269) 686-3238, E-mail: nicholas.gallagher@perrigo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-present-at-the-ubs-global-consumer-and-retail-conference-302702947.html
SOURCE Perrigo Company plc